Power Law company profile

Tessera Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2018 Unicorn

A new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source

Valuation

$1–2.5B

Latest valuation · 2026

Unlock exact value

Revenue

$100–500M

Latest reported FY

Unlock exact value

Headcount

100–500

Current team size

Unlock exact value

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

16 investors on Tessera Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 16 investors entered at this stage

Artis Ventures

Abu Dhabi Investment Authority

SoftBank

University of California

Berkeley

Longevity Vision Fund

Altitude Life Science Ventures

Cormorant Asset Management

Regeneron Pharmaceuticals

SALT Fund

T. Rowe Price

Qatar Investment Authority

March Capital Partners

Alaska Permanent Fund

Hanwha Impact

Flagship Pioneering

Tessera Therapeutics mafia

Startups founded by Tessera Therapeutics alumni

Former Tessera Therapeutics employees who went on to start their own companies. Sorted by Dealroom signal score.

Liberate BioEst. 2022

Michael J MitchellUnited States

Signal score84

Generate BiomedicinesEst. 2020

Molly GibsonUnited States

Signal score75

Sana BiotechnologyEst. 2018

Jacob Rubens.United States

Signal score69

Apriori BioEst. 2020

Noubar AfeyanUnited States

Signal score66

Via ScientificEst. 2022

MMMelissa J. MooreUnited States

Signal score58

Book a demo to explore the full alumni network →

Global footprint

Where Tessera Therapeutics has talent and traffic

AI talent share

2.3% of workforce is AI talent
(5 of 216 staff)

Core AI52.31%

Other AI00%

Non-AI workforce21197.69%

Workforce by country

2 countries with
team presence

🇺🇸 United States98.9%

🇮🇹 Italy1.1%

2 countries shown

Web traffic by country

8.6K monthly visits
across markets

🇺🇸 United States74.4%

🇬🇧 United Kingdom12.8%

🇮🇳 India3.5%

🇵🇭 Philippines3.5%

🇯🇵 Japan2.3%

Top 5 markets shown

Patent intelligence

$354k patent portfolio · 6 active families

Estimated portfolio value

$354k

0.02% of valuation · 5726.8× smaller than top peer Ablynx ($2B)

6 active patent families

Where Tessera Therapeutics innovates Molecular biologyCell biologyNanoparticlePharmaceutical drugGenome

Where Tessera Therapeutics concentrates vs peers

Each axis is a top-10 topic across Tessera Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Tessera Therapeutics

An AI-synthesized read of the highest-engagement posts about Tessera Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tessera Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles